Related Experiment Video
Updated: May 21, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Telitacicept for refractory IgA nephropathy: a case series.
Xun-Jie Ma1, Jia-Xin Liu1, Wei-Guang Yang1
1Department of Nephrology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Journal of Nephrology
|May 20, 2026
Summary
Telitacicept effectively treated IgA nephropathy (IgAN) by reducing proteinuria and improving kidney function. Benefits persisted even after discontinuing the drug, offering a promising therapy for IgAN patients.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- IgA nephropathy (IgAN) is characterized by mesangial IgA deposition, driven by galactose-deficient IgA1 (Gd-IgA1) from activated B cells.
- Telitacicept targets B-cell activation, presenting a potential therapeutic strategy for IgAN.
Purpose of the Study:
- To evaluate the efficacy and safety of telitacicept in patients with refractory IgA nephropathy.
- To assess the durability of therapeutic benefits after telitacicept discontinuation.
Main Methods:
- A study involving 9 patients with refractory IgAN receiving subcutaneous telitacicept for 12 months, followed by a 6-month withdrawal period.
- Dosage: 160 mg weekly for 6 months, then 160 mg bi-weekly for 6 months.
- Laboratory data were collected throughout the 18-month follow-up (12 months treatment + 6 months withdrawal).
Main Results:
- All patients achieved complete proteinuria remission after 12 months of telitacicept therapy.
- Estimated glomerular filtration rate (eGFR) improved and remained stable post-treatment.
- Complete remission was sustained 6 months after drug withdrawal, with 6 patients discontinuing conventional IgAN treatments.
Conclusions:
- Telitacicept demonstrates significant efficacy in reducing proteinuria and enhancing kidney function in refractory IgAN.
- The observed therapeutic effects of telitacicept are durable and maintained after treatment cessation.
- Telitacicept represents a safe and effective treatment option for IgA nephropathy, potentially allowing discontinuation of other therapies.
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...